Preparing For The Return Of US FDA Inspections
FY2020 review highlights drop in inspections, preparations for growing backlog, and pandemic test of Janet Woodcock’s 21st Century proposition – developments that will likely reverberate in the years ahead.
You may also be interested in...
US FDA 'resilience' report charts how inspection backlog grew and impacted approvals and compliance follow-up.
With more experience, the US FDA was able to standardize record review requests and timing.
Records reviews are common now in lieu of an in-person inspection for US generic applications, but more virtual facility checks could be coming soon.